Liver study tests how MCI-186 behaves in severe impairment
NCT ID NCT03664544
First seen Jan 08, 2026 · Last updated Jun 19, 2026 · Updated 26 times
Summary
This completed Phase 1 study looked at how the drug MCI-186 (Edaravone) is processed in the body of people with severe liver impairment compared to healthy individuals. Twelve participants received a single intravenous dose. The goal was to measure drug levels and safety, not to treat any condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Centre
Prague, Czechia
-
Investigational Centre
Miskolc, Hungary
-
Investigational Centre
Bratislava, Slovakia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MCI-186 (Edaravone, Radicava, Radicut)
What this could lead to
If successful, this study could help doctors understand how to safely dose MCI-186 in patients with severe liver problems.
What could go wrong
This is a very small, early-phase study (12 people) focused on drug processing, not on treating any disease. Results may not apply to broader populations or predict real-world safety.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.